MediciNova director granted 44,500 stock options

MediciNova Inc. director Nagao Hideki received a grant of 44,500 stock options for Common Stock.

Rhea-AI Filing Summary

MediciNova Inc. director Nagao Hideki received a grant of 44,500 stock options for Common Stock. The options have an exercise price of $1.36 per share and expire on June 22, 2036. Following this grant, Nagao holds 44,500 stock options directly.

The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the company. This is a compensation-related award rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 44,500 shares

Grant/Award 1 txn

Insider Nagao Hideki

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	44,500	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 44,500 contracts (Direct)

Footnotes (1)

1. F1. The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the Company.

Key Figures

Option grant size: 44,500 options Exercise price: $1.36 per share Shares underlying options: 44,500 shares +2 more

5 metrics

Option grant size 44,500 options Stock Option (Right to Buy) awarded to director Nagao Hideki

Exercise price $1.36 per share Conversion or exercise price of granted stock options

Shares underlying options 44,500 shares Underlying MediciNova Common Stock tied to the new options

Post-grant option holdings 44,500 options Total options held following the reported transaction

Option expiration date June 22, 2036 Expiration of the granted stock options

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, underlying security, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

underlying security financial

"underlying_security_title: Common Stock"

vesting financial

"The option vests in four equal installments on September 30, 2026..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MediciNova (MNOV) director Nagao Hideki report in this Form 4?

Nagao Hideki reported receiving a grant of 44,500 stock options for MediciNova Common Stock. These options are a compensation-related award, not an open-market trade, and give the right to buy shares at a fixed exercise price.

How many MediciNova (MNOV) stock options were granted and at what exercise price?

The filing shows a grant of 44,500 stock options with an exercise price of $1.36 per share. This price is the cost at which the director can buy MediciNova Common Stock when the options are exercised.

When do Nagao Hideki’s MediciNova (MNOV) options vest?

The 44,500 options vest in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027. Vesting is contingent on Nagao continuing to provide service to MediciNova through each vesting date.

When do the MediciNova (MNOV) stock options granted to Nagao Hideki expire?

The options expire on June 22, 2036. After this expiration date, any unexercised portion of the 44,500 stock options will lapse, meaning the right to buy MediciNova shares at the $1.36 exercise price ends.

Is this MediciNova (MNOV) Form 4 a stock purchase or sale?

No, it records a grant of stock options as compensation, coded as an acquisition (A) rather than an open-market buy or sell. The director did not trade existing shares; he received rights to buy future shares at a set price.

How many MediciNova (MNOV) options does Nagao Hideki hold after this grant?

After the reported grant, the Form 4 shows Nagao holding 44,500 stock options directly. This figure reflects his position in this specific option award following the transaction as disclosed in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2026 - 04:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nagao Hideki

(Last) (First) (Middle)

C/O MEDICINOVA, INC.

4275 EXECUTIVE SQUARE, SUITE 300

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MEDICINOVA INC [ MNOV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.36	06/23/2026		A		44,500		(1)	06/22/2036	Common Stock	44,500	$0	44,500	D

Explanation of Responses:

1. The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the Company.

	/s/ Yuichi Iwaki, attorney-in-fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)